Previous 10 | Next 10 |
BERKELEY HEIGHTS, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of an underwritten...
Cyclacel Pharmaceuticals (CYCC) trades 10.7% down after hours on planning to offer shares for sale in an underwritten public offering; underwriters granted 30-day option to purchase up to an additional 15% of the shares.Offer size, terms not yet disclosed.Net proceeds to be used for...
Cyclacel Pharmaceuticals (CYCC) announces that it intends to offer shares for sale in an underwritten public offering.Intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares.Cyclacel did not provide further financial details on the offering.The comp...
BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it intends to offer share...
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2020 Results Conference Call February 25, 2021 04:30 PM ET Company Participants Jason Assad - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Officer Dr. Ma...
Cyclacel Pharmaceuticals (CYCC): Q4 GAAP EPS of -$2.74 misses by $2.21.As of December 31, 2020, cash and cash equivalents totaled $33.4 million. Additional proceeds of $4.3 million were received from the exercise of warrants after December 31, 2020. Based on current spending, the proforma cas...
BERKELEY HEIGHTS, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results and business hig...
BERKELEY HEIGHTS, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2020 fina...
BERKELEY HEIGHTS, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the...
Gainers: Ceragon Networks (CRNT) +67%.ObsEva (OBSV) +60%.Polar Power (POLA) +50%.Charah Solutions (CHRA) +46%.Avinger (AVGR) +45%.DBV Technologies (DBVT) +42%.Novan (NOVN) +42%.Senseonics (SENS) +42%.Atlantic Power (AT) +40%.Driven Brands (DRVN) +31%.Losers: Dogness (DOGZ)...
News, Short Squeeze, Breakout and More Instantly...
Cyclacel Pharmaceuticals Inc. Company Name:
CYCC Stock Symbol:
NASDAQ Market:
A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) rose 1.6% to $12 on volume of 162,538,711 shares Safe & Green Holdings Corp. (SGBX) rose 52.0% to $0.219 on volume of 135,670,644 shares Tesla Inc. (TSLA) rose 5.0% to $170.18 on volume of 124,333,134 shares...
A look at the top 10 most actives in the United States Safe & Green Holdings Corp. (SGBX) rose 52.1% to $0.2192 on volume of 34,842,044 shares Processa Pharmaceuticals Inc. (PCSA) rose 46.9% to $2.38 on volume of 31,858,013 shares PROSHARES TRUST (SQQQ) rose 5.0% to $12.4002 on volume...
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP;...